PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.76 CNY 1.02% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaBlock Sciences Nanjing Inc
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Deferred Income Tax
ÂĄ22.2m
CAGR 3-Years
4%
CAGR 5-Years
82%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Deferred Income Tax
ÂĄ255m
CAGR 3-Years
28%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Deferred Income Tax
ÂĄ22.5m
CAGR 3-Years
-23%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Deferred Income Tax
ÂĄ85.1m
CAGR 3-Years
65%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Deferred Income Tax
ÂĄ91.3m
CAGR 3-Years
18%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Deferred Income Tax?
Deferred Income Tax
22.2m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Deferred Income Tax amounts to 22.2m CNY.

What is PharmaBlock Sciences Nanjing Inc's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 5Y
82%

Over the last year, the Deferred Income Tax growth was 18%. The average annual Deferred Income Tax growth rates for PharmaBlock Sciences Nanjing Inc have been 4% over the past three years , 82% over the past five years .

Back to Top